Company profile
Zhejiang Carbiogene Therapeutics Co., Ltd.
Privately held: no public share price (Verified via web search: a privately held Hangzhou/Zhejiang, China biotech developing CAR-T and tumor immunotherapy candidates (e.g. anti-ILT3 CAR-T); no public listing found. Sources: https://clinicaltrials.gov/study/NCT06705725 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | BCMACell therapy | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.